Drug Trial Radar · NCT03349333
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Sep 10, 2015
Primary completion
Jul 21, 2017
Study completion May 21, 2018
Sponsor
- Lead sponsor
- Mundipharma (China) Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).
Conditions
- Refractory Peripheral T-Cell Lymphoma
- Relapsed T-Cell Lymphoma
Interventions
pralatrexateDrug
Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
Vitamin B12 and folic acidDietary supplement
The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate(ORR) by International Working Group CriteriaTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.